PERSPECTIVE THERAPEUTICS, INC. (CATX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
27/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCATX / S&P -18.23% / 15.20% |
LoseCATX / S&P CATX unavailable / 15.00% |
LoseCATX / S&P -2.21% / 50.40% |
| 2026-Q11/3 |
WinCATX / S&P 51.64% / -4.33% |
LoseCATX / S&P CATX unavailable / 11.30% |
LoseCATX / S&P 12.00% / 27.70% |
| 2025-Q40/3 |
LoseCATX / S&P -19.83% / 2.65% |
LoseCATX / S&P CATX unavailable / 9.00% |
LoseCATX / S&P 12.00% / 13.40% |
| 2025-Q30/3 |
LoseCATX / S&P -0.29% / 8.12% |
LoseCATX / S&P CATX unavailable / 4.61% |
LoseCATX / S&P -3.23% / 13.45% |
| 2025-Q21/3 |
WinCATX / S&P 61.50% / 10.94% |
LoseCATX / S&P CATX unavailable / 4.83% |
LoseCATX / S&P -20.47% / 10.63% |
| 2025-Q10/3 |
LoseCATX / S&P -33.23% / -4.27% |
LoseCATX / S&P CATX unavailable / 4.98% |
LoseCATX / S&P -35.23% / 10.57% |
| 2024-Q40/3 |
LoseCATX / S&P -76.10% / 2.41% |
LoseCATX / S&P CATX unavailable / 5.25% |
LoseCATX / S&P -25.60% / 6.15% |
| 2024-Q31/3 |
WinCATX / S&P 33.90% / 5.89% |
LoseCATX / S&P CATX unavailable / 5.89% |
LoseCATX / S&P CATX unavailable / 6.11% |
| 2024-Q20/3 |
LoseCATX / S&P -16.22% / 4.28% |
LoseCATX / S&P CATX unavailable / 5.38% |
LoseCATX / S&P CATX unavailable / 5.12% |
| 2024-Q11/3 |
WinCATX / S&P 197.50% / 10.56% |
LoseCATX / S&P CATX unavailable / 5.71% |
LoseCATX / S&P CATX unavailable / 5.59% |
| 2023-Q41/3 |
WinCATX / S&P 48.15% / 11.69% |
LoseCATX / S&P CATX unavailable / 6.81% |
LoseCATX / S&P CATX unavailable / 7.78% |
| 2023-Q30/3 |
LoseCATX / S&P -59.70% / -3.27% |
LoseCATX / S&P -119.03% / 7.52% |
LoseCATX / S&P CATX unavailable / -5.03% |
| 2023-Q20/3 |
LoseCATX / S&P 4.69% / 8.74% |
LoseCATX / S&P -119.31% / 9.50% |
LoseCATX / S&P CATX unavailable / -8.57% |
| 2023-Q11/3 |
WinCATX / S&P 156.00% / 7.50% |
LoseCATX / S&P -109.82% / 10.77% |
LoseCATX / S&P CATX unavailable / -15.69% |
| 2022-Q41/3 |
WinCATX / S&P 8.70% / 7.56% |
LoseCATX / S&P -100.00% / 11.88% |
LoseCATX / S&P CATX unavailable / -17.99% |
| 2022-Q30/3 |
LoseCATX / S&P -25.81% / -4.88% |
LoseCATX / S&P -2.79% / 13.47% |
LoseCATX / S&P CATX unavailable / -1.41% |
| 2022-Q21/3 |
WinCATX / S&P -13.89% / -16.10% |
LoseCATX / S&P 7.38% / 13.71% |
LoseCATX / S&P CATX unavailable / 11.04% |
| 2022-Q10/3 |
LoseCATX / S&P -7.69% / -4.60% |
LoseCATX / S&P 14.32% / 15.97% |
LoseCATX / S&P CATX unavailable / 42.23% |
| 2021-Q40/3 |
LoseCATX / S&P -38.10% / 11.03% |
LoseCATX / S&P 7.96% / 15.00% |
LoseCATX / S&P CATX unavailable / 96.40% |
| 2021-Q30/3 |
LoseCATX / S&P -21.25% / 0.58% |
LoseCATX / S&P 4.96% / 10.77% |
LoseCATX / S&P CATX unavailable / 69.42% |
| 2021-Q20/3 |
LoseCATX / S&P -26.61% / 8.55% |
LoseCATX / S&P 3.85% / 6.58% |
LoseCATX / S&P CATX unavailable / 51.81% |
| 2021-Q12/3 |
WinCATX / S&P 142.22% / 6.17% |
WinCATX / S&P 3.18% / -1.06% |
LoseCATX / S&P CATX unavailable / 7.39% |
| 2020-Q41/3 |
LoseCATX / S&P -22.41% / 12.15% |
WinCATX / S&P 18.32% / -3.72% |
LoseCATX / S&P CATX unavailable / -33.42% |
| 2020-Q31/3 |
LoseCATX / S&P 3.57% / 8.93% |
WinCATX / S&P 20.85% / -2.04% |
LoseCATX / S&P CATX unavailable / -27.10% |
| 2020-Q21/3 |
LoseCATX / S&P 5.66% / 20.54% |
WinCATX / S&P 32.35% / -0.46% |
LoseCATX / S&P CATX unavailable / -27.11% |
| 2020-Q12/3 |
WinCATX / S&P -14.52% / -19.60% |
WinCATX / S&P 33.35% / 3.47% |
LoseCATX / S&P CATX unavailable / -14.75% |
| 2019-Q42/3 |
WinCATX / S&P 93.75% / 9.07% |
WinCATX / S&P 26.00% / 5.36% |
LoseCATX / S&P CATX unavailable / 2.99% |
| 2019-Q31/3 |
LoseCATX / S&P -21.95% / 1.70% |
WinCATX / S&P 28.58% / 5.02% |
LoseCATX / S&P CATX unavailable / 0.21% |
| 2019-Q22/3 |
WinCATX / S&P 10.81% / 4.30% |
WinCATX / S&P 23.48% / 6.64% |
LoseCATX / S&P CATX unavailable / 8.65% |
| 2019-Q12/3 |
WinCATX / S&P 23.33% / 13.65% |
WinCATX / S&P 22.90% / 8.12% |
LoseCATX / S&P CATX unavailable / 14.29% |
| 2018-Q41/3 |
LoseCATX / S&P -42.31% / -13.52% |
WinCATX / S&P 23.02% / 9.05% |
LoseCATX / S&P CATX unavailable / 18.23% |
| 2018-Q31/3 |
WinCATX / S&P 15.56% / 7.71% |
LoseCATX / S&P CATX unavailable / 10.21% |
LoseCATX / S&P CATX unavailable / 19.06% |
| 2018-Q21/3 |
WinCATX / S&P 7.14% / 3.43% |
LoseCATX / S&P CATX unavailable / 9.03% |
LoseCATX / S&P CATX unavailable / 14.46% |
| 2018-Q11/3 |
WinCATX / S&P 5.00% / -0.76% |
LoseCATX / S&P CATX unavailable / 7.68% |
LoseCATX / S&P CATX unavailable / 12.46% |
| 2017-Q40/3 |
LoseCATX / S&P -23.08% / 6.64% |
LoseCATX / S&P CATX unavailable / 7.03% |
LoseCATX / S&P CATX unavailable / 13.82% |
| 2017-Q30/3 |
LoseCATX / S&P -17.46% / 4.48% |
LoseCATX / S&P CATX unavailable / 5.68% |
LoseCATX / S&P CATX unavailable / 17.57% |
| 2017-Q21/3 |
WinCATX / S&P 6.78% / 3.09% |
LoseCATX / S&P CATX unavailable / 4.83% |
LoseCATX / S&P CATX unavailable / 17.74% |
| 2017-Q10/3 |
LoseCATX / S&P 1.72% / 6.07% |
LoseCATX / S&P CATX unavailable / 3.67% |
LoseCATX / S&P CATX unavailable / 13.32% |
| 2016-Q40/3 |
LoseCATX / S&P -19.44% / 3.82% |
LoseCATX / S&P CATX unavailable / 2.09% |
LoseCATX / S&P CATX unavailable / 7.05% |
| 2016-Q30/3 |
LoseCATX / S&P -17.24% / 3.85% |
LoseCATX / S&P CATX unavailable / 0.20% |
LoseCATX / S&P CATX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CATX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -5.36% | 20.78% |
| Annualized return | -5.36% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CATX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -51.08% | 83.14% |
| Annualized return | -13.32% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CATX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -57.60% | 319.30% |
| Annualized return | -8.22% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |